Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1

被引:84
作者
Hanna, Nadine
Montagner, Alexandra
Lee, Wen Hwa
Miteva, Maria
Vidal, Michel
Vidaud, Michel
Parfait, Beatrice
Raynal, Patrick
机构
[1] Univ Paris 05, INSERM, U745, Fac Sci Pharmaceut & Biol, F-75270 Paris 06, France
[2] Hop Purpan, INSERM, U563, Dept Lipoprot & Med Lipid, F-31024 Toulouse 03, France
[3] Univ Oxford, Struct Genom Consortium, Oxford OX4 7LD, England
[4] Univ Paris 05, INSERM, U648, UFR Biomed, F-75006 Paris, France
关键词
LEOPARD syndrome; PTPN11; SHP-2 phosphatase activity; Gab1; PI3K;
D O I
10.1016/j.febslet.2006.03.088
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
LEOPARD (LS) and Noonan (NS) are overlapping syndromes associated with distinct mutations of SHP-2. Whereas NS mutations enhance SHP-2 catalytic activity, we show that the activity of three representative LS mutants is undetectable when assayed using a standard protein tyrosine phosphatase (PTP) substrate. A different assay using a specific SHP-2 substrate confirms their decreased PTP activity, but also reveals a significant activity of the T468M mutant. In transfected cells stimulated with epidermal growth factor, the least active LS mutants promote Gab1/PI3K binding, validating our in vitro data. LS mutants thus display a reduced PTP activity both in vitro and in transfected cells. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:2477 / 2482
页数:6
相关论文
共 14 条
[1]   Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2 [J].
Cunnick, JM ;
Mei, L ;
Doupnik, CA ;
Wu, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (26) :24380-24387
[2]   Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene [J].
Digilio, MC ;
Conti, E ;
Sarkozy, A ;
Mingarelli, R ;
Dottorini, T ;
Marino, B ;
Pizzuti, A ;
Dallapiccola, B .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (02) :389-394
[3]   Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation [J].
Fragale, A ;
Tartaglia, M ;
Wu, J ;
Gelb, BD .
HUMAN MUTATION, 2004, 23 (03) :267-277
[4]   Crystal structure of the tyrosine phosphatase SHP-2 [J].
Hof, P ;
Pluskey, S ;
Dhe-Paganon, S ;
Eck, MJ ;
Shoelson, SE .
CELL, 1998, 92 (04) :441-450
[5]   Diverse biochemical properties of Shp2 mutants [J].
Keilhack, H ;
David, FS ;
McGregor, M ;
Cantley, LC ;
Neel, BG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) :30984-30993
[6]   PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects [J].
Kontaridis, MI ;
Swanson, KD ;
David, FS ;
Barford, D ;
Neel, BG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) :6785-6792
[7]   Noonan syndrome type I with PTPN11 3 bp deletion:: structure-function implications [J].
Lee, WH ;
Raas-Rotschild, A ;
Miteva, MA ;
Bolasco, G ;
Rein, A ;
Gillis, D ;
Vidaud, D ;
Vidaud, M ;
Villoutreix, BO ;
Parfait, B .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 58 (01) :7-13
[8]   A novel role for Gab1 and SHP2 in epidermal growth factor-induced ras activation [J].
Montagner, A ;
Yart, A ;
Dance, M ;
Perret, B ;
Salles, JP ;
Raynal, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (07) :5350-5360
[9]   The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling [J].
Neel, BG ;
Gu, HH ;
Pao, L .
TRENDS IN BIOCHEMICAL SCIENCES, 2003, 28 (06) :284-293
[10]   Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease [J].
Tartaglia, M ;
Martinelli, S ;
Stella, L ;
Bocchinfuso, G ;
Flex, E ;
Cordeddu, V ;
Zampino, G ;
van der Burgt, I ;
Palleschi, A ;
Petrucci, TC ;
Sorcini, M ;
Schoch, C ;
Foà, R ;
Emanuel, PD ;
Gelb, BD .
AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (02) :279-290